Industry Strength Score
36/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
PHAXIAM Therapeutics SA (PHXM) Stock Price & Overview
NASDAQ:PHXM • US29604W2070
Current stock price
3.1 USD
-0.02 (-0.64%)
At close:
3.1 USD
0 (0%)
After Hours:
The current stock price of PHXM is 3.1 USD. Today PHXM is down by -0.64%. In the past month the price decreased by -29.55%.
PHXM Key Statistics
1-Month Range2.5 - 4.57
Current PHXM stock price positioned within its 1-month range.
- Market Cap
- 18.832M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.04
- Dividend Yield
- N/A
PHXM Stock Performance
Today
-0.64%
1 Week
+13.14%
1 Month
-29.55%
3 Months
-31.42%
Longer-term
6 Months -38.00%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
PHXM Stock Chart
PHXM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PHXM.
Chartmill TA Rating
Chartmill Setup Rating
PHXM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHXM. Both the profitability and financial health of PHXM have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PHXM Earnings
Next Earnings DateMar 20, 2024
Last Earnings DateNov 14, 2023
PeriodQ3 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
PHXM Forecast & Estimates
8 analysts have analysed PHXM and the average price target is 10.17 USD. This implies a price increase of 228.04% is expected in the next year compared to the current price of 3.1.
For the next year, analysts expect an EPS growth of 77.73% and a revenue growth -100% for PHXM
Analysts
Analysts85
Price Target10.17 (228.06%)
EPS Next Y77.73%
Revenue Next Year-100%
PHXM Financial Highlights
Over the last trailing twelve months PHXM reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 99.68% compared to the year before.
Income Statements
Revenue(TTM)6.65M
Net Income(TTM)-228.00K
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.35% | ||
| ROE | -0.62% | ||
| Debt/Equity | 0.3 |
Chartmill High Growth Momentum
EPS Q2Q%-1025.16%
Sales Q2Q%-70.86%
EPS 1Y (TTM)99.68%
Revenue 1Y (TTM)59.04%
PHXM Ownership
Ownership
Inst Owners0.01%
Shares6.07M
Float5.91M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
PHXM Industry Overview
PHXM operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
21%
Outperformed 21% of sub-industries
3 Month Rank
21%
Outperformed 21% of sub-industries
6 Month Rank
36%
Outperformed 36% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.7%
- Average Profit Margin
- 29.7%
- Average Operating Margin
- 25.9%
- Average P/E
- 38.6
- Average Fwd P/E
- 30.5
- Average Debt/Equity
- 0.0
PHXM Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PHXM
Company Profile
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
Company Info
IPO: 2013-05-07
PHAXIAM Therapeutics SA
60 avenue Rockefeller
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 49
Phone: 33478744438
PHAXIAM Therapeutics SA / PHXM FAQ
What does PHXM do?
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
What is the stock price of PHAXIAM Therapeutics SA today?
The current stock price of PHXM is 3.1 USD. The price decreased by -0.64% in the last trading session.
Does PHAXIAM Therapeutics SA pay dividends?
PHXM does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHXM stock?
PHXM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting PHXM stock to perform?
8 analysts have analysed PHXM and the average price target is 10.17 USD. This implies a price increase of 228.04% is expected in the next year compared to the current price of 3.1.
Can you provide the market cap for PHAXIAM Therapeutics SA?
PHAXIAM Therapeutics SA (PHXM) has a market capitalization of 18.83M USD. This makes PHXM a Nano Cap stock.
Who owns PHAXIAM Therapeutics SA?
You can find the ownership structure of PHAXIAM Therapeutics SA (PHXM) on the Ownership tab.